Chargement en cours...
Chimeric antigen receptor T cell therapies for multiple myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. There is an unmet need to develop novel therapies for refractory/rela...
Enregistré dans:
| Publié dans: | J Hematol Oncol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6873434/ https://ncbi.nlm.nih.gov/pubmed/31752943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0823-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|